Article ; Online: A case of prazosin in treatment of rapid eye movement sleep behavior disorder.
2023 Volume 20, Issue 2, Page(s) 319–321
Abstract: Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by dream-enactment behaviors that emerge during a loss of REM sleep atonia. Untreated RBD carries risks for physical injury from falls or other traumatic events during dream ... ...
Abstract | Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by dream-enactment behaviors that emerge during a loss of REM sleep atonia. Untreated RBD carries risks for physical injury from falls or other traumatic events during dream enactment as well as risk of injury to the bed partner. Currently, melatonin and clonazepam are the mainstay pharmacological therapies for RBD. However, therapeutic response to these medications is variable. While older adults are most vulnerable to RBD, they are also particularly vulnerable to the adverse effects of benzodiazepines, including increased risk of falls, cognitive impairment, and increased risk of Alzheimer disease. Prazosin is a centrally active alpha-1 adrenergic receptor antagonist often prescribed for trauma nightmares characterized by REM sleep without atonia in patients with posttraumatic stress disorder. We report a case of successful RBD management with prazosin in a patient in whom high-dose melatonin was ineffective. Although there was no observable reduction in dream-enactment behaviors with high-dose melatonin, the possibility of a synergistic effect of prazosin combined with melatonin cannot be ruled out. This case report supports further evaluation of prazosin as a potential therapeutic for RBD. Citation: Cho Y, Iliff JJ, Lim MM, Raskind M, Peskind E. A case of prazosin in treatment of rapid eye movement sleep behavior disorder. |
---|---|
MeSH term(s) | Humans ; Aged ; Melatonin/therapeutic use ; REM Sleep Behavior Disorder/complications ; REM Sleep Behavior Disorder/drug therapy ; Prazosin/therapeutic use ; Clonazepam/therapeutic use ; Stress Disorders, Post-Traumatic/complications |
Chemical Substances | Melatonin (JL5DK93RCL) ; Prazosin (XM03YJ541D) ; Clonazepam (5PE9FDE8GB) |
Language | English |
Publishing date | 2023-10-26 |
Publishing country | United States |
Document type | Case Reports |
ZDB-ID | 2397213-0 |
ISSN | 1550-9397 ; 1550-9389 |
ISSN (online) | 1550-9397 |
ISSN | 1550-9389 |
DOI | 10.5664/jcsm.10888 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6590: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.